Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016

08 Jun 2010 • by Natalie Aster

GlobalData, the industry analysis specialist, has released its latest report, “Allergic Conjunctivitis - Drug Pipeline Analysis and Market Forecasts to 2016” which provides the key data, information and analysis on the allergic conjunctivitis market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with allergic conjunctivitis, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the allergic conjunctivitis market.

The Allergic Conjunctivitis Market is Forecast To Grow At A Lower Rate Between 2009 and 2016

GlobalData estimated the allergic conjunctivitis market in 2009 to be $1,069m. Allergic conjunctivitis is the most common type of eye allergy and is widely experienced by the global population. The incidence appears to be on the increase, possibly due to air pollution and allergens worldwide. The global allergic conjunctivitis market in 2009 primarily comprised of drug classes which included anti-histamines, mast cell stabilizers, dual action agents, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid products. The current market has many treatment options from different classes of therapies. The use of generic formulations from these classes has also demonstrated the curious dynamics in the allergic conjunctivitis market. Overall, between 2009 and 2016, the allergic conjunctivitis market is expected to grow at a Compound Annual Growth Rate (CAGR) of only 2% and reach $1,234m by 2016.

The Current Competition In The Allergic Conjunctivitis Market Is Strong

GlobalData found that the current competition in the allergic conjunctivitis market is strong. The currently used classes of therapies in allergic conjunctivitis are effective against the disease and has the market dominated by brands, generics and off-label formulations which have high patient affordability. Several topically used products from anti-histamines and mast cell stabilizers classes and use of topical corticosteroids and NSAID (in cases of chronic conditions) are currently managed for the treatment of ocular allergies with good efficacy and safety profiles.

Weak Pipeline Stagnating The Future Growth Of The Allergic Conjunctivitis Market

GlobalData found that the pipeline in the allergic conjunctivitis market is weak. It lacks innovation and contains only 17 molecules, out of which 24% are in Phase III, 52% are in Phase II and the rest 24% are in Phase I and Preclinical development. The late-stage clinical development pipeline is weak. However, the early-stage pipeline is moderately strong as these molecules target the chronic stages of allergic conjunctivitis, such as Vernal Kerato-Conjunctivitis (VKC), Atopic Kerato-Conjunctivitis (AKC) and allergic rhino-conjunctivitis. Additionally, these pipeline molecules will need to be more successful at increasing patient compliance by reducing the frequency of drug administration, and should demonstrate promise in treating chronic allergic conditions in the coming years.

The Allergic Conjunctivitis Market Has Significant Opportunities For The Treatment Of Chronic Forms Of Ocular Allergies

GlobalData found that the allergic conjunctivitis market is well served by the currently available treatment options from different classes of therapy. However, the ocular allergic market has significant opportunities for novel products that have the potential to address chronic forms of ocular allergies. This is because the current treatment options do not serve the unmet needs in treating severe forms of allergic conjunctivitis. Additionally, Over the Counter (OTC) medications have shown a better market penetration in the sales of anti-allergic eye drops annually in treating exacerbated ocular allergic conditions. The ocular allergic market is also gearing up to launch novel products for treating both ocular and nasal allergic conditions simultaneously, which have the potential to treat both allergic rhinitis and allergic conjunctivitis (together referred as allergic rhino-conjunctivitis).

About GlobalData

GlobalData is an industry analysis specialist company providing business information products and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.